RecruitingNot ApplicableNCT06538610
The 5-FU Holter Study
Feasibility Study of Ambulatory Holter Monitoring While Receiving Infusional Fluorouracil (5-FU) Chemotherapy
Sponsor
University of Auckland, New Zealand
Enrollment
10 participants
Start Date
Nov 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
To assess the feasibility of using ambulatory ECG monitoring (Holter monitor) for patients receiving 5-FU chemotherapy
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Patients with diagnosis of gastrointestinal malignancy
- Planned to receive either FOLFOX chemotherapy with any treatment intent
- Aged ≥ 18 years at time of signing informed consent form
Exclusion Criteria1
- • ECG with left bundle branch block or left ventricular hypertrophy with strain
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEHolter monitor
Holter monitor fitted from start of 5-FU infusion (Day 1) to 5-FU infusion ending (Day 3). Holter monitor to be worn for approximately 46-48 hours.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06538610